- Marker Therapeutics Inc to Participate in the Beyond CAR-T: What's Next for Cell Therapy Event TranscriptAug 09, 2023
- Marker Therapeutics Inc to Host Clinical Program Update Call TranscriptFeb 16, 2022
- Marker Therapeutics Inc at Raymond James Human Health Innovation Conference (Virtual) TranscriptJun 21, 2021
- Q1 2021 Marker Therapeutics Inc Earnings Call TranscriptMay 12, 2021€19.1 (-1.04%)Earnings
- Q3 2020 Marker Therapeutics Inc Earnings Call TranscriptNov 09, 2020€12.7 (+8.55%)Earnings
- Marker Therapeutics Inc MultiTAA-Specific T Cell Therapy in Patients with Pancreatic Adenocarcinoma at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting TranscriptJun 01, 2020
- Q1 2020 Marker Therapeutics Inc Earnings Call TranscriptMay 11, 2020€22.8 (+8.57%)Earnings
- Q3 2019 Marker Therapeutics Inc Earnings Call TranscriptNov 12, 2019€35.64 (-0.03%)Earnings
- Marker Therapeutics Inc Special Call TranscriptJul 22, 2019
- Marker Therapeutics Inc at Bank of America Merrill Lynch Health Care Conference TranscriptMay 16, 2019
Marker Therapeutics Inc to Host Clinical Program Update Call Transcript
Good afternoon, ladies and gentlemen, and welcome to Marker Therapeutics conference call. (Operator Instructions) As a reminder, this conference call is being recorded. It's now my pleasure to turn the call over to Mr. Tony Kim, Chief Financial Officer at Marker. Mr. Kim, please go ahead.
Thanks, operator. Welcome, everyone, and thank you for joining us this afternoon for our clinical program and technical operations update call. With me today are Peter Hoang, our President and Chief Executive Officer; Dr. Juan Vera, our Chief Scientific and Chief Operating Officer; and Dr. Mythili Koneru, our Chief Medical Officer.
This afternoon, we issued a news release that you can find on our website at markertherapeutics.com which include the summary of initial results and the safety lead-in portion of our Phase II AML trial as well as updates on our new manufacturing process and an overview of our near-term clinical plans.
Before we begin, as a reminder, we will be making forward-looking statements
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)